The O-PRISM score was introduced for risk assessment in children transferred to intensive care following BMT. The aim of this study is to determine the prognostic value of a serial evaluation of the O-PRISM score. Ninety-three children, 58 allogeneic-related and 35 unrelated BMT, were evaluated. At weekly intervals, the O-PRISM was calculated based on the standard PRISM score and the three additional variables CRP, GVHD and hemorrhage. Overall survival was 0.51 ؎ 0.05 (48/93 patients). Seventeen children died of recurrent disease and 28 of BMTrelated complications. High O-PRISM scores significantly correlated with adverse outcome. The relative risks of DOC of patients with scores у10 compared to patients with lower scores were: day 0: 3.9 (95% confidence-interval: 1.1-13.7, P = 0.02), day 7: 2.0 (0.7-6.2, P = 0.20), day 14: 5.2 (1.9-14.0, P = 0.001), day 21: 5.6 (1.9-16.5, P = 0.001), day 28: 11.5 (3.8-100.9, P Ͻ 0.001), day 35: 7.3 (1.9-27.7, P = 0.001). As early as day 0, children with scores у10 points showed a higher cumulative incidence of DOC than patients with lower scores (0.69 ؎ 0.15 vs 0.27 ؎ 0.05, P = 0.02). The O-PRISM score represents a useful clinical parameter for serial risk assessment following BMT. As it indicates fatal events early, it may be helpful for parent information and even more for the early establishment of intensified supportive treatment. The O-PRISM score may therefore be a valuable parameter for the evaluation of different strategies for BMT and supportive treatment.
neoplasms, as well as from chronic bone marrow failure. However, BMT is associated with a substantial risk of potentially life-threatening acute complications, as well as significant chronic organ toxicity. In some patients, BMTrelated complications are superimposed on pre-existing chronic organ insufficiency, such as renal insufficiency related to previous nephrotoxic treatment. In addition, almost all patients entering BMT treatment show significant immunosuppression, either due to cytostatic or immunosuppressive pre-treatment or as a result of their underlying disease. These pre-existing factors, as well as BMT-related parameters such as the toxicity of the conditioning regimen, infection or GVHD, may all contribute to the clinical course after BMT and ultimately determine outcome.
In recent years, much progress has been made in combating these problems with intensified supportive therapy. In addition, novel BMT strategies have been developed such as less intensive conditioning therapy or alternative immunosuppressive strategies to avoid some of the BMT toxicity. 1, 2 However, a significant number of patients remain who experience a complicated clinical course and ultimately die as a result of BMT-related toxicity. Although some of these patients develop complications early during marrow aplasia, the majority of patients suffers from more subacute or chronic complications leading to a stepwise deterioration in clinical condition and ultimately to multiorgan dysfunction (MOD). 3, 4 Considerable research has focused on those patients who require intensive care treatment following BMT, and it has been demonstrated repeatedly that the development of MOD is associated with poor outcome. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] In several reports, acute GVHD has been identified as the major risk factor associated with MOD and the need of ICU treatment. 15, 16 In addition, infection and gastrointestinal hemorrhage have been described as prognostically unfavorable. 5, 17 On the basis of these studies, it has been proposed that some of these patients might benefit from earlier intensification of supportive therapy and timely referral to the intensive care unit (ICU). 5, 18, 19 However, to date there are no validated and standardized clinical parameters that allow early identification of patients who might benefit from early referral. This dilemma is reflected in the significant variability of the proportion of patients referred to ICU follow-ing BMT, which is probably due to different referral strategies in different BMT centers.
In this context, prognostic scores such as the PRISM and APACHE have also been evaluated in patients admitted to ICU because of life-threatening complications after BMT. [5] [6] [7] [8] [9] [11] [12] [13] [14] These studies produced variable results, and in most reports, the scores failed to accurately predict the outcome of patients after BMT. [5] [6] [7] 9, [11] [12] In addition, the scoring systems showed a tendency to underestimate mortality in the post-BMT setting. 8, 12 This may be attributed to the fact that these scoring systems do not take BMTrelated parameters into account. 20, 21 Led by this consideration, we introduced the Oncological Pediatric Risk of Mortality (O-PRISM) Score, which combines the Pediatric Risk of Mortality (PRISM) score with BMT-related parameters that have been prognostically relevant in the analysis of prognostic factors after referral to ICU (Table 1) . 5 In this previous analysis, we evaluated BMT patients at the time of admission to ICU. In this article, we present the data on the serial evaluation of the O-PRISM score in 93 patients after allogeneic BMT, treated at the Düsseldorf Pediatric Stem Cell Transplantation Center during a 10-year period. This analysis significantly expands our previous work as it also documents the timely course of BMTrelated complications. The study evaluates a standardized score for its ability to detect those patients early who show a stepwise clinical deterioration during the course of BMT treatment, finally resulting in MOD and death. HLA-mismatch situations, an anti-CD-25 antibody was administered as described previously. 22 
Patients and methods

Patients
Clinical and laboratory parameters, O-PRISM score
The complete medical records including BMT-related data, conditioning regimen and BMT complications were prospectively recorded. Clinical parameters such as heart and respiration rate, blood pressure, and oxygen saturation were closely monitored. Laboratory values were measured daily (blood count, serum electrolytes, CRP, bilirubin, creatinine, urea), every other day (liver enzymes, LDH), twice weekly (coagulation profiles) or more frequently if indicated. Therapeutic measures such as hemodynamic and ventilator support (after referral to ICU) or hemodialysis/ hemofiltration were recorded in detail. If parameters such as blood gas analysis were not obtained on a regular basis, as there was no clinical indication for this analysis, normal results were assumed and zero point calculated for this parameter in the O-PRISM score.
Based on these prospectively recorded data, the PRISM and O-PRISM scores were retrospectively calculated ( Table 1 ). The PRISM score is based on 14 physiologic parameters. 21 The O-PRISM score supplements the PRISM score with the three additional parameters severity of acute GVHD (grade 0-1, 0 points; grade 2, 2 points; grade 3-4, 4 points), CRP level (Ͻ10 mg/dl, 0 points; у10 mg/dl, 4 points), and presence of macroscopic hemorrhage (none, 0 points; present, 4 points) ( Table 1) . 5 In order to allow for a standardized and concise evaluation of hemorrhage, only such bleeding events were counted, which resulted in an Hb-loss of more than 1 g/dl per day, or which necessitated continuous erythrocyte transfusion. Thus, our criteria for including bleeding events into the score have been more precisely defined compared to the case in our previous study.
Statistical analysis
All data were analyzed using contingency tables. Categorical data were calculated with the Pearson 2 test, and continuous numeric data were analyzed with the MannWhitney U test. Survival as well as the cumulative risk of fatal events such as death from disease (DOD) and death from complications (DOC) during follow-up were estimated according to the Kaplan-Meier method, and putative prognostic parameters were evaluated with the log-rank test. All tests were two-sided, and P values below 0.05 were considered significant.
Results
Hematologic neoplasms such as ALL/NHL (36 patients), AML/MDS (25 patients) or CML (six patients) were the most frequent underlying diagnoses, followed by chronic bone marrow failure due to severe aplastic anemia or Fanconi anemia (12 patients) ( Table 2) . Among these patients, there was no significant difference in the relative frequencies of related or unrelated transplants with regard to diagnosis. Conversely, all seven patients suffering from solid tumors received transplants from related donors. The underlying disease did not signifi- cantly affect outcome. Only patients with solid tumors derived no benefit from BMT as all died either from relapse or complications (Table 3) . 23 The survival rate of all patients was 0.51 Ϯ 0.05 (48 of 93 patients). Overall survival after related (0.56 Ϯ 0.07, 33 of 58 patients) and unrelated BMT (0.43 Ϯ 0.08, 15 of 35 patients) was similar ( Figure 1 ). However, after unrelated BMT, the risk of DOC was higher than after related BMT (17 of 35 patients vs 11 of 58 patients), whereas the risk of DOD was lower (3 of 35 patients vs 14 of 58 patients).
Twenty-two patients (11 patients after related and unrelated BMT, respectively) were referred to ICU, mostly as a result of ventilator-dependent respiratory insufficiency. These patients have been reported previously. 5 Median duration of ICU treatment was 4 (1-32) days. Eleven of these patients were discharged from ICU (related BMT, seven patients; unrelated BMT, four patients), and four patients (all after related BMT) are long-term survivors. All patients admitted to ICU following unrelated BMT ultimately died as a result of transplant-related complications.
Oncological pediatric risk of mortality score
On serial evaluation, the O-PRISM score showed a biphasic course with higher scores during marrow aplasia and a second rise in some patients 6 to 10 weeks after BMT. The O-PRISM scores were variable, and the majority of patients had negative or low scores (below 10 points). Underlying disease, type of transplant (related vs unrelated), recipient CMV status or type of immunosuppression did not correlate with the O-PRISM score. However, the 55 patients who received TBI during conditioning showed significantly higher mean scores during the early phase after BMT than did the 38 patients who received conditioning without TBI.
High O-PRISM scores у10 points correlated with survival, particularly with the risk of DOC (Figure 2 ). The mean O-PRISM scores for survivors and those patients who died as a result of recurrent disease were similar. Table 4 summarizes the relative risk of DOC during the course of BMT treatment for patients with O-PRISM scores у10 points. This analysis shows that patients who later died of complications had significantly higher O-PRISM scores as early as day 0, than did those who survived or died of recurrent disease (Figure 2 ). Only on day 7 after BMT was the estimation of relative risk borderline significant (Table 4) . This was mainly attributable to the fact that more patients who survived showed higher scores intermittently (mainly due to infection or hemorrhage during aplasia).
Estimation of the cumulative risk of DOC with regard to The number n reflects the number of patients who were cared for at the transplantation unit at a defined time-point. O-PRISM scores were not calculated after discharge from the transplantation unit.
O-PRISM scores supports the relative risk calculation. This analysis reveals that on day 0, patients with high O-PRISM scores have a cumulative risk of DOC as high as 0.69 Ϯ 0.15 ( Figure 3) . Visualization of the time course of the O-PRISM scores ( Figure 4 ) reveals that rise in O-PRISM у10 points preceded DOC by 1 week in two patients, and by 2 or more weeks in 22 patients. Five DOC patients showed no rise above 10 points during the observation period (when evaluated at weekly intervals on the BMT unit). In addition, comparison with DOD patients and survivors shows that in the latter groups patients mostly have no or only limited periods with a significant rise in O-PRISM scores. Lastly, this analysis also demonstrates that the vast majority of DOCs occurs within the first 6 months after BMT, indicating that some patients were stabilizable at least for a limited time beyond engraftment (Figures 3 and 4) . In the analysis of the 22 patients admitted to ICU, those patients who were able to be discharged from ICU had lower scores on referral to ICU than did those who died on ICU (see also our previous analysis 5 ). ICU patients who died on ICU or later during treatment had higher scores than did survivors or patients who died as a result of disease recurrence (median 18.2 vs 8.2 points, P Ͻ 0.05).
Analysis of prognostic factors
The three additional parameters included in the O-PRISM score all constitute relevant early prognostic parameters. High CRP serum levels (in most instances associated with uncontrolled severe infections), severity of GVHD as well as the presence of macroscopic hemorrhage correlated with an increased transplantation-related mortality. Remarkably, the presence and severity of macroscopic hemorrhage (evaluated by the impact of hemorrhage on hemoglobin levels) was an early prognostic marker and correlated with overall survival (eg on day 7: no hemorrhage: 0.60 Ϯ 0. -7  0  7  14  21  28  35  42  49  56  63  70   -7  0  7  14  21  28  35  42  49  56 leukocyte engraftment (day 28 and beyond) correlated with poor prognosis, whereas temporarily high CRP levels during marrow aplasia did not significantly affect outcome. In the analysis of the 'oncological' and 'non-oncological' parameters of the O-PRISM score, the traditional PRISM score alone did not accurately correlate with outcome. However, the additional oncological parameters alone did not consistently provide reliable prognostic information at all evaluated time points, either. Although high PRISM scores correlated with pathologic oncological parameters, only the combined evaluation of all parameters allowed a clear correlation of the score with outcome.
The analysis of the three patients who underwent a second transplant after a further relapse (marked by an asterisk in Figure 4 ) emphasizes the data of the other patients. Two patients who either survived disease-free or Bone Marrow Transplantation died due to tumor recurrence showed no marked elevation of the O-PRISM scores, whereas the patients who died as a result of transplantation-related complications repeatedly showed high O-PRISM scores up to 18 points.
Discussion
It is a general clinical phenomenon that the individual patient's response to a specific treatment may be highly variable. This is very true for such intensive treatments as BMT, particularly when patients receiving BMT have had significant pretreatment. Many physicians involved in this field will appreciate that there are some patients who undergo BMT with only mild to moderate, and mostly acute toxicity, whereas others develop severe and some-times life-threatening complications early on during BMT. The latter patients may be stabilized for a limited time, but often develop further and more sustained complications which may lead to a stepwise deterioration in the clinical situation and ultimately to MOD and death. Clinical experience may be helpful in identifying such patients early. However, there are no standardized, well validated and reproducible clinical tools available to date that may help to predict an individual patient's outcome at a very early stage of BMT. Prior to BMT treatment, some clinical parameters such as the underlying disease, specific pretreatment and HLA disparity with the donor may be helpful for risk assessment. 22, 24 In addition, some molecular polymorphisms have been evaluated which may be causative in the variable course after BMT. 25 Nevertheless, the introduction of diagnostic tools that allow for standardized risk assessment of children during BMT treatment may still have a significant impact for the development and evaluation of therapeutic strategies in individual patients, as well as for the analysis of cohorts of BMT patients. In this context, prognostic scoring systems such as the PRISM and APACHE score have been repeatedly evaluated, and most studies have focused on patients who required referral to ICU after BMT. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] In these studies, the scores have been calculated only once at referral to ICU, and there are no data available from the literature concerning these scores early after transplantation in the non-ICU setting. The analyses mentioned yielded variable results with regard to prognosis following referral to ICU as did the prognostic scores. This may at least partly be explained by the fact that the decision to make an ICU referral is not necessarily based on a defined pathophysiologic constellation, but on other factors such as referral strategies, availability of ICU support and conceptional considerations (eg inclusion of postoperative care patients) may also be relevant.
In contrast to the studies of prognostic scores at referral to ICU mentioned our serial analysis of the O-PRISM score is not affected by such strategic considerations, but only reflects the patients' clinical condition. In addition, the O-PRISM score includes important BMT-related parameters such as parameters of infection, GVHD and hemorrhage that are by themselves relevant risk factors for adverse outcome. 5, 17 The current analysis reveals that in the non-ICU setting also, the O-PRISM score distinguishes prognostic subgroups among children following allogeneic BMT. Compared to the PRISM score, the O-PRISM score shows a higher accuracy in predicting outcome. Remarkably, high O-PRISM scores as early as on day 0 distinguish a subset of patients with a high risk of DOC, even although some patients may survive for several months (Figures 1, 3 and  4) . Although this retrospective study suggests that the O-PRISM score may help to recognize high risk patients early during the course of BMT treatment, one has to bear in mind that due to the large confidence intervals of the score, it is inappropriate to make decisions, for example, concerning life support at a defined score cut-off level. 26 On the other hand, it appears adequate to compare cohorts of patients on the basis of high scores for the evaluation of alternative supportive treatment strategies, such as new immunosuppressive regimen or immunomodulatory approaches. Thus, the O-PRISM score constitutes an objective measure of morbidity after SCT that may be meaningful in such future studies.
Our serial evaluation may lead to the conclusion that early events such as severe mucositis, infection, VOD and capillary leakage syndrome -probably facilitated by the individual patients' response to conditioning treatment -lead into a vicious circle that with present supportive strategies can hardly be overcome. The development of acute GVHD and the ensuing immunologic imbalances may be another significant event that maintains this vicious circle. In our analysis, five of 12 patients with high O-PRISM on day 0 later developed acute GVHD grade 3 or 4, thus underscoring the above-mentioned consideration. This hypothesis is further substantiated by experimental work demonstrating that cytokine-mediated early reactions to conditioning treatment correlate with the risk of GVHD and outcome. 24 In addition, conditioning treatment may significantly affect the complement system and coagulation parameters, thereby provoking severe acute complications such as VOD and capillary leakage syndrome. 22, 25, 27, 28 Our analysis of the O-PRISM score demonstrates the early prognostic impact of the O-PRISM score and thus provides evidence that these experimental observations may be of significant clinical relevance. In addition, the O-PRISM score may help to identify a group of high-risk patients early who may benefit from alternative supportive strategies.
Furthermore, our analysis also demonstrates that although some patients may be stabilized for several weeks or even months early toxicity affects outcome significantly. To a certain extent, this observation reflects a failure of current supportive care and the need of novel supportive strategies. In the light of the above-mentioned experimental data, one might assume that immunomodulatory therapies (eg TNF-␣ blocking reagents) that interrupt the vicious cycle of interdependent complications such as infection, GVHD and intensified immunosuppression more specifically, may result in a significant improvement in the success of supportive care.
Much research activity in the field of BMT has focused on the evaluation of indication, timing, conditioning and immunosuppressive therapy with specific diagnoses. In many of these studies, therapeutic success was evaluated predominantly in the light of the parameters of survival and transplantation-related mortality. However, with such significant advances having now been achieved, long-term side-effects such as risk of secondary tumors, long-term organ toxicity and quality of life after SCT become more relevant. In addition to these parameters, a physiology-based scoring system such as the O-PRISM may be a meaningful measure of acute toxicity and morbidity after SCT. It may therefore be valuable for the comparison of different therapeutic strategies for conditioning or immunosuppressive therapy in a defined clinical diagnosis. In such studies, the addition of a prognostically relevant score which also reflects acute morbidity to the parameters of survival and long-term toxicity may therefore provide meaningful information.
In conclusion, the O-PRISM score may be valuable for the comparison of different therapeutic strategies for BMT and supportive care. The scoring parameters can be ascertained during what should be considered routine clinical evaluation of BMT patients. Hence, the O-PRISM can be obtained with little effort during the daily management of patients. The O-PRISM score may not only be valuable for parent or patient counseling, but it may also help to establish an individual patient's supportive care strategy. Lastly, the O-PRISM score may be valuable in the evaluation of novel therapeutic strategies, such as immunomodulative treatment, as the score allows for a standardized evaluation of BMT-related toxicity and prognosis based on relevant physiologic parameters.
